Cited 10 times in
Monophosphoryl lipid A (MPL) upregulates major histocompatibility complex (MHC) class I expression by increasing interferon-gamma (IFN-gamma)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이봉기 | - |
dc.date.accessioned | 2019-11-26T01:13:18Z | - |
dc.date.available | 2019-11-26T01:13:18Z | - |
dc.date.issued | 1999 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/172838 | - |
dc.description.abstract | Tumor immunity is primarily mediated by cells as CD8+ cytotoxic T lymphocytes (CTL) recognize tumor antigen by MHC class I molecules. But most tumors are associated with a decreased expression of MHC class I to escape the antitumor immunity of the host. Our previous data have demonstrated that MPL has an antitumor effect on metastatic lung cancer of B16 melanoma with enhancing cytotoxicity due to increase of IFN-gamma and IL-2, and decrease of IL-4, which indicates the stimulation of type 1 helper T cells (Th1). To determine the effects of MPL, IFN-gamma, TNF-alpha, and IL-1 alpha on MHC class I expression of B16 melanoma cells, we evaluated the expression of MHC class I molecules with treatments of MPL, IFN-gamma, TNF-alpha, and IL-1 alpha by flow cytometry. The supernatant of MPL-treated spleen cells in vitro upregulated the expression of MHC class I molecules of B16 melanoma cells compared to the control supernatant of spleen cells. The MHC class I expression of B16 melanoma cells treated with IFN-gamma, but not TNF-alpha or IL-1 alpha, increased in a time-dependent manner. In conclusion, MPL upregulated MHC class I expression of B16 melanoma cells by activating spleen cells via IFN-gamma. These data suggest that increased IFN-gamma by MPL is responsible for the upregulation of MHC class I expression to augment cytotoxicity. Therefore, we suggest that MPL could play an important role in immunotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adjuvants, Immunologic/pharmacology* | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Histocompatibility Antigens Class I/biosynthesis* | - |
dc.subject.MESH | Interferon-gamma/biosynthesis* | - |
dc.subject.MESH | Interferon-gamma/pharmacology | - |
dc.subject.MESH | Lipid A/analogs & derivatives* | - |
dc.subject.MESH | Lipid A/pharmacology | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Inbred C57BL | - |
dc.subject.MESH | Tumor Cells, Cultured | - |
dc.subject.MESH | Up-Regulation | - |
dc.title | Monophosphoryl lipid A (MPL) upregulates major histocompatibility complex (MHC) class I expression by increasing interferon-gamma (IFN-gamma) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Microbiology (미생물학교실) | - |
dc.contributor.googleauthor | Chul Ho Cho | - |
dc.contributor.googleauthor | Bong Kee Lee | - |
dc.contributor.googleauthor | Seung Min Kwak | - |
dc.contributor.googleauthor | Joo Deuk Kim | - |
dc.identifier.doi | 10.3349/ymj.1999.40.1.20 | - |
dc.contributor.localId | A02806 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 10198602 | - |
dc.subject.keyword | Monophosphoryl lipid A | - |
dc.subject.keyword | MHC class I | - |
dc.subject.keyword | IFN-γ | - |
dc.contributor.alternativeName | Lee, Bong Ki | - |
dc.contributor.affiliatedAuthor | 이봉기 | - |
dc.citation.volume | 40 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 20 | - |
dc.citation.endPage | 25 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.40(1) : 20-25, 1999 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.